page_banner

Products

3-Hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine Cas: 65-23-6 White powder

Short Description:

Catalog Number: XD90442
Cas: 65-23-6
Molecular Formula: C8H11NO3
Molecular Weight: 169.18
Availability: In Stock
Price:  
Prepack: 25g USD10
Bulk Pack: Request Quote

 

 

 

 

 

 


Product Detail

Product Tags

Catalog Number XD90442
Product Name 3-Hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine

CAS

65-23-6

Molecular Formula

C8H11NO3

Molecular Weight

169.18
Storage Details Ambient
Harmonized Tariff Code 29362500

 

Product Specification

Appearance White powder
Assay >99%
Density Same retention time
Residue on ingnition <0.5%
Identification Positive reaction
Loss on Drying <0.5%
Acidity 2.6

 

Two mutations in the cystathionine beta-synthase (CBS) gene were found in two Japanese siblings with pyridoxine non-responsive homocystinuria who had different methionine levels in their blood during the neonatal period. Both patients were compound heterozygotes of two mutant alleles: one had an A-to-G transition at nucleotide 194 (A194 G) that caused a histidine-to-arginine substitution at position 65 of the protein (H65R), while the other had a G-to-A transition at nucleotide 346 (G346A) which resulted in a glycine-to-arginine substitution at position 116 of the protein (G116R). The two mutant proteins were separately expressed in Escherichia coli, and they completely lacked catalytic activity. Despite their identical genotypes and almost equal protein intake, these siblings showed different levels of blood methionine during the neonatal period, suggesting that the level of methionine in blood is determined not only by the defect in the CBS gene and protein intake, but also by the activity of other enzymes involved in methionine and homocysteine metabolism, especially during the neonatal period. Therefore, high-risk newborns who have siblings with homocystinuria, even if the level of methionine in their blood is normal in a neonatal mass screening, should be followed up and diagnosed by an assay of enzyme activity or a gene analysis so that treatment can be begun as soon as possible to prevent the development of clinical symptoms. In addition, a new, more sensitive method for the mass screening of CBS deficiency in neonates should be developed.


  • Previous:
  • Next:

  • Close

    3-Hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine Cas: 65-23-6 White powder